Primary Mesenchymal Tumors of the Brain, So-Called Reticulum Cell Sarcoma

Troland, Charles E.; Sahyoun, Philip F.; Mandeville, Frederick B.

doi:10.1097/00005072-195007000-00006

Cited by 26 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All three of these tumours showed histological appearances consistent with Hodgkin's sarcoma. In the absence of any evidence of a multicentric origin we agree with Troland, Sahyoun and Mandeville (1950) On admission there, his physical signs were unaltered. X-ray of the skull showed no abnormality, but an E.E.G.…”

Section: Martin Andsupporting

confidence: 80%

“…* A number of writers have reported cases of primary reticulum-cell sarcoma of the brain. These cases have been reviewed by Troland, Sahyoun and Mandeville in 1950, who conclude that they should be grouped among the primary mesenchymal tumours of the brain and not as malignant lymphomata. In this group they also include cases of primary Hodgkin's sarcoma and primary lymphosarcoma of the brain.…”

Section: Young and Gysin (1945) (mentioning

confidence: 99%

See 1 more Smart Citation

Intracranial Manifestations of Malignant Lymphoma

John¹,

Nabarro²

1955

Br J Cancer

View full text Add to dashboard Cite

show abstract

Section: Martin Andsupporting

confidence: 80%

Section: Young and Gysin (1945) (mentioning

confidence: 99%

Intracranial Manifestations of Malignant Lymphoma

John¹,

Nabarro²

1955

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…DUNNING and FÜRTH [6] consider that microglia and histiocytes are morphologically and functionally identical and that both represent progressive steps in the maturation of a single, more primitive, cell type. JOHN and NABARRO [15], in agreement with TROLAND et al [22], believe that in the absence of a multicentric origin, both Hodgkin's sarcoma and reticulum cell sarcoma of the brain should be excluded from the malignant lymphomas and grouped, together with Perithelial and Spindle Cell Sarcomas, as "primary mesenchymal tumours of the brain".…”

Section: Fig 3 Tumour Cells Lying Within the Lumen Of A Vein (H And Ementioning

confidence: 71%

Intracerebral Hodgkin's Granuloma: Report of a case and review of the literature

Ljungdahl¹,

Strang²,

Tovi³

1965

Minim Invasive Neurosurg

View full text Add to dashboard Cite

pictures Symtoms and signs of disordered function of the nervous system occur in from ten to fifteen per cent of cases of Hodgkin's disease [10]. DIAMOND [5], in a review of 1583 verified cases, found neurological complications in 205 (12,9%). This latter figure included herpes zoster (52 cases), cranial nerve (20 cases) and peripheral nerve (48 cases) involvement. Symtoms and signs referable to the central nervous system occurred in 75 cases and affected the spinal cord in 50 (3,2%) and the brain in 25 (1,6%); Although this study was based on clinical evidence alone, the results are almost identical with those reported by GOLDMAN [9] who found verified invasion of the central nervous system in 10 of 212 cases (4,7%).The above figures however, give little information pertinent to the frequency of verified symptomatic tumour masses within the cranial cavity. The infrcquency of such cases is clearly evident in the report of JOHN and NABARRO [15], who found only 8 verified cases in a review of the literature to 1955, to which they added one of their own from a total of 175 cases.

show abstract

“…In 1948, Russell and colleagues ( 9 ) termed this cancer “microglioma” based on research suggesting that silver carbonate had affinity for microglia rather than for primitive reticulocytes. In 1950, Troland and colleagues ( 10 ) observed that the reticulum was not a tumor component in their cases and proposed the term “primary mesenchymal tumor of the brain” based on the similarity in morphology and behavior of tumor cells to mesenchymal tissues. By 1966, Rappaport ( 11 ) proposed the first clinically relevant classification of lymphoma based on cell morphology, and PCNSL was called “diffuse histiocytic lymphoma”.…”

Section: Historical Evolutionmentioning

confidence: 99%

Relapsed Primary Central Nervous System Lymphoma: Current Advances

2021

View full text Add to dashboard Cite

Primary central nervous system lymphoma is an invasive malignant lymphoma confined to the central nervous system. Although patients undergoing first-line treatment can achieve complete response, most of them still relapse within two years. Relapsed lymphoma is derived from occult lymphoma cells, and B cell receptor pathway activation and immune escape are the key mechanisms for the pathogenesis of PCNSL. Most relapses are in the central nervous system, a small number of relapses are isolated systemic relapses, and clinical symptoms occur early and vary. Current treatments for relapse include high-dose methotrexate rechallenge and other regimens of chemotherapy, whole-brain radiation therapy, hematopoietic stem-cell transplantation, targeted therapy and immunotherapy, which have become promising treatments. The overall prognosis of relapsed PCNSL is very poor, although it is affected by many factors. This article summarizes the mechanisms, related factors, clinical features, follow-up, treatment and prognosis of relapsed primary central nervous system lymphoma.

show abstract

Primary Mesenchymal Tumors of the Brain, So-Called Reticulum Cell Sarcoma

Cited by 26 publications

References 0 publications

Intracranial Manifestations of Malignant Lymphoma

Intracranial Manifestations of Malignant Lymphoma

Intracerebral Hodgkin's Granuloma: Report of a case and review of the literature

Relapsed Primary Central Nervous System Lymphoma: Current Advances

Contact Info

Product

Resources

About